Emergency Management in a Dedicated Respiratory Unit of Patients With a Possible COVID-19 Infection

NCT04371328 | Completed

• 1 other identifier: RC31/20/0094
• Study Type: observational
• Target: 1,860
• Locations: 1 country
• Sites: 1

Brief Summary

This research aims to improve knowledge of the epidemiology of patients consulting in the COvid Possible REspiratory Units (RECOP unit). Indeed, the epidemic linked to COVID19 affects France and impacts its health system. The reception of all intermediate patients will be on the Emergency Structures (SU). Indeed, the French healthcare system centralizes unscheduled urgent care on the ER. The aspecific respiratory symptomatology in "intermediate" patients indicates them all the more at an admission to SU or the diagnostic approach to respiratory difficulty may be carried out. It will be necessary to identify the diagnosis of the dyspneic patient and to define his virological status COVID before referring him to the appropriate units. The investigatory propose an original strategy of dedicating entire care sectors to the care of patients admitted for dyspnea in our ER. These units will be named RECOP units. This study would improve epidemiological knowledge of COVID-19 and ability to receive these patients within the SU.

Conditions

Emergencies

Keywords

COVID 19; aspecific respiratory symptomatology

Outcome Measures

Primary Outcomes (1)

• Describe the characteristics of patients admitted to reCOP units according to their virological status vis-à-vis COVID-19

  The virological condition will be taken with PCR tests on naso-pharyngeal samples or on sputum for patients taking

  30 days

Secondary Outcomes (1)

• Develop a predictive model of the risk of being COVID for patients admitted to the emergency room for dyspnea

  0 days

Other Outcomes (2)

• Virological status

  30 days

• Mortality status

  30 days

Interventions

RECOP unit patient OTHER

All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified. 30 days after inclusion, virological status and mortality will be collect

Eligibility Criteria

• Age: 15 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

all patient admitted to the RECOP unit for dyspnea will be inclued in this clinical trial

You may qualify if:

• All patients over the age of 15 admitted to the RECOP unit for dyspnea

You may not qualify if:

• Patient admitted to shock for respiratory distress requiring immediate respiratory support.
• Patient under justice safeguard

Sponsors & Collaborators

• University Hospital, Toulouse: lead

Study Sites (1)

University Hospital of Toulouse

Toulouse, 31000, France

Location

MeSH Terms

Conditions

Emergencies; COVID-19

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Frédéric Balen, MD

  University Hospital of Toulouse

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Month
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 29, 2020
• First Posted: May 1, 2020
• Study Start: March 13, 2020
• Primary Completion: June 5, 2020
• Study Completion: June 30, 2020
• Last Updated: October 8, 2021

Record last verified: 2021-10

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)